Quick Answer
MYRIAD GENETICS INC reported Cash And Cash Equivalents At Carrying Value of $149.60 million for the year ending 2025.
- MYRIAD GENETICS INC showed an increase of +46.1% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from MYRIAD GENETICS INC's annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2010 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2010 to 2025), MYRIAD GENETICS INC's Cash And Cash Equivalents At Carrying Value has grown by 61.1%.
- Historical annual values: Fiscal year 2025: $149.60 million | Fiscal year 2024: $102.40 million | Fiscal year 2023: $132.10 million | Fiscal year 2022: $56.90 million | Fiscal year 2021: $257.40 million | Fiscal year 2020: $117.00 million | Fiscal year 2020: $163.70 million | Fiscal year 2019: $93.20 million | Fiscal year 2018: $110.90 million | Fiscal year 2017: $102.40 million | Fiscal year 2016: $68.50 million | Fiscal year 2015: $64.10 million | Fiscal year 2014: $64.80 million | Fiscal year 2013: $104.10 million | Fiscal year 2012: $86.40 million | Fiscal year 2011: $52.68 million | Fiscal year 2010: $92.84 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: